8-K: Intellia Reports Q4/FY25 Results, Lonvo-z Phase 3 Data Mid-2026

Intellia Therapeutics announced its fourth quarter and full-year 2025 financial results and provided key business updates on its CRISPR gene editing programs, lonvo-z and nex-z.

Summary

• Lonvo-z Phase 3 HAELO clinical data is expected by mid-2026, with a Biologics License Application (BLA) submission in the second half of 2026 and an anticipated U.S. launch in the first half of 2027.
• The process is underway to reactivate global sites for the MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN, with enrollment completion expected in the second half of 2026.
• Engagement with the FDA is ongoing to resolve the clinical hold on the MAGNITUDE Phase 3 clinical trial of nex-z in ATTR-CM.
• Intellia ended 2025 with approximately $605.1 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2027.
• The net loss for the fourth quarter of 2025 was $95.8 million, an improvement from a net loss of $128.9 million in the fourth quarter of 2024.
• Collaboration revenue increased to $23.0 million for the fourth quarter of 2025, up from $12.9 million for the same period in 2024.
• Research and development (R&D) expenses decreased to $88.7 million for the fourth quarter of 2025, compared to $116.9 million for the fourth quarter of 2024.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed update. While lonvo-z shows strong progress towards commercialization and one clinical hold was lifted, the significant cash burn and the persistent clinical hold on the MAGNITUDE trial for nex-z introduce notable uncertainty and risk.

Positives

• Lonvo-z Phase 3 HAELO clinical data is expected by mid-2026, with BLA submission in the second half of 2026 and anticipated U.S. launch in the first half of 2027.
• Positive longer-term Phase 1/2 clinical data for lonvo-z in HAE showed durable reductions in plasma kallikrein and prolonged attack-free status for up to 32 months.
• Market research indicated 99% of HAE patients would be at least somewhat likely to take lonvo-z if prescribed, and 92% of healthcare providers would prescribe a product with its profile.
• The FDA lifted the clinical hold on the IND for MAGNITUDE-2 for nex-z in ATTRv-PN on January 27, 2026, and enrollment resumption is underway.
• Positive follow-up data from the Phase 1 clinical trial of nex-z in ATTR-CM showed consistent and durable reductions in serum TTR and stability or improvement in multiple markers of cardiomyopathy.
• Net loss decreased to $95.8 million in Q4 2025 from $128.9 million in Q4 2024, and to $412.7 million for FY 2025 from $519.0 million for FY 2024.
• Collaboration revenue increased by $10.1 million in Q4 2025 compared to Q4 2024, partly driven by $9.0 million from a terminated license and collaboration agreement.
• R&D expenses decreased by $28.2 million in Q4 2025 compared to Q4 2024, primarily due to lower employee-related expenses, stock-based compensation, research materials, and contracted services.
• Cash, cash equivalents, and marketable securities are expected to fund operations into the second half of 2027, through lonvo-z's anticipated U.S. commercial launch.

Negatives

• A clinical hold remains on the MAGNITUDE Phase 3 clinical trial of nex-z for ATTR-CM, with ongoing engagement with the FDA to resolve it.
• Cash, cash equivalents, and marketable securities decreased to $605.1 million as of December 31, 2025, from $861.7 million as of December 31, 2024, representing a $256.6 million reduction.

Risks

• Uncertainty exists regarding when the clinical hold on the MAGNITUDE trial for nex-z in ATTR-CM may be resolved, including potential required actions.
• Uncertainties are related to Intellia's ability to resume the MAGNITUDE and MAGNITUDE-2 trials, further develop nex-z, and provide updated guidance.
• Risks are associated with Intellia's ability to protect and maintain its intellectual property position.
• Risks are related to Intellia's relationships with third parties, including contract manufacturers, collaborators, licensors, and licensees.
• Uncertainties exist regarding the authorization, initiation, and conduct of preclinical and clinical studies and other development requirements for product candidates, including regulatory approvals.
• Risks are related to the ability to successfully develop and commercialize any one or more of Intellia's product candidates, including lonvo-z for HAE.
• Risks exist that results from preclinical studies or clinical studies may not be predictive of future results in subsequent studies.
• There is a risk that clinical study results will not be positive.
• Risks are related to the potential delay of planned clinical trials due to regulatory feedback or other developments.
• Risks are associated with collaborations, such as with Regeneron, not continuing or not being successful.

Future Outlook

Intellia Therapeutics expects a pivotal year ahead, highlighted by topline Phase 3 data and planned BLA submission for lonvo-z by mid-2026 and in the second half of 2026, respectively, with an anticipated U.S. launch in the first half of 2027. The company is also focused on completing patient enrollment in the MAGNITUDE-2 trial by the second half of 2026 and resolving the clinical hold on the MAGNITUDE trial for nex-z. Operations are expected to be funded into the second half of 2027.

Management Comments

• "2025 was a time of accomplishment and resiliency for Intellia as we presented encouraging longer term Phase 1/2 clinical data for both lonvo-z and nex-z, rapidly enrolled patients in our three Phase 3 trials, commenced activities to prepare for a potential lonvo-z launch in HAE and responded to the clinical holds on our nex-z Phase 3 trials late in the year."
• "We expect the year ahead to be a pivotal one, highlighted by our topline Phase 3 data and planned BLA submission for lonvo-z, which has the potential to transform the HAE treatment paradigm by freeing most patients from both their attacks and chronic therapy."
• "Additionally, we are focused on resuming our forward momentum with nex-z by completing patient enrollment in MAGNITUDE-2 and resolving the clinical hold on MAGNITUDE."

Industry Context

StockSavvy.ai notes that Intellia's progress in CRISPR gene editing for HAE and ATTR amyloidosis positions it at the forefront of a rapidly evolving therapeutic landscape. The potential for one-time, curative treatments like lonvo-z and nex-z could significantly disrupt existing chronic treatment paradigms, offering substantial benefits to patients and market share to early innovators. The ongoing regulatory scrutiny, as evidenced by the clinical holds, highlights the inherent risks and high bar for safety and efficacy in novel gene-editing therapies, a common challenge across the industry.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies' projects or results. However, the market research indicating high patient and physician interest in lonvo-z's profile suggests a strong competitive position against existing HAE treatments, which often require chronic administration.
• For ATTR amyloidosis, nex-z's potential for deep, consistent, and lifelong TTR reduction after a single treatment aims to surpass the efficacy and convenience of current therapies, such as RNAi therapeutics (e.g., Onpattro, Amvuttra from Alnylam) or TTR stabilizers (e.g., Vyndaqel/Vyndamax from Pfizer), by targeting the root cause with a single dose.

Stakeholder Impact

• Shareholders: Potential for significant value creation if lonvo-z successfully launches and nex-z clinical holds are resolved; however, ongoing cash burn and clinical trial risks pose financial uncertainty.
• Patients (HAE): High potential for a transformative, one-time treatment (lonvo-z) that could dramatically reduce or eliminate attacks and chronic therapy burden.
• Patients (ATTR Amyloidosis): Potential for a one-time treatment (nex-z) to halt and reverse disease progression, offering significant improvement over current therapies, but progress is currently impacted by regulatory holds.
• Employees: Continued focus on advancing clinical programs and preparing for commercial launch suggests stable to growing opportunities, particularly in commercial roles.
• Collaborators (Regeneron): Continued collaboration on nex-z, with shared development and commercialization efforts, subject to clinical trial progress and regulatory approvals.

Next Steps

• Present four posters at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place February 27 March 2, 2026.
• Report HAELO topline data by mid-2026.
• Submit a Biologics License Application (BLA) to the U.S. FDA for lonvo-z in the second half of 2026, if data are supportive.
• Build field sales and reimbursement teams for lonvo-z in 2026.
• Finalize distribution models for lonvo-z in 2026.
• Identify U.S. treatment centers for lonvo-z in 2026.
• Advance pricing and access planning strategy for lonvo-z in 2026.
• Resume MAGNITUDE-2 enrollment and complete it in the second half of 2026.
• Resolve the clinical hold on the MAGNITUDE Phase 3 clinical trial of nex-z for ATTR-CM.

Key Dates

Recommendation

Intellia Therapeutics presents a mixed bag of developments. The strong progress and positive market reception for lonvo-z in HAE, coupled with the lifting of one clinical hold for nex-z, are significant positives. However, the substantial cash burn and the unresolved clinical hold on the MAGNITUDE trial for ATTR-CM introduce considerable risk and uncertainty. Investors should hold to monitor the upcoming lonvo-z Phase 3 data, the BLA submission timeline, and the resolution of the remaining nex-z clinical hold, as these events will be critical determinants of future valuation.

Keywords

CRISPR gene editing, HAE, ATTR amyloidosis, lonvo-z, nex-z, biopharmaceutical, clinical trials, FDA, BLA submission, gene therapy, rare disease, Intellia Therapeutics, NTLA